{"nctId":"NCT00300469","briefTitle":"Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood","startDateStruct":{"date":"2006-03"},"conditions":["Mixed Dyslipidemia","Coronary Heart Disease","Dyslipidemia"],"count":613,"armGroups":[{"label":"A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABT-335","Drug: Atorvastatin"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABT-335","Drug: Atorvastatin"]},{"label":"C","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: ABT-335","Drug: Placebo"]},{"label":"D","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Atorvastatin","Drug: Placebo"]},{"label":"E","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Atorvastatin","Drug: Placebo"]},{"label":"F","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Atorvastatin","Drug: Placebo"]}],"interventions":[{"name":"ABT-335","otherNames":[]},{"name":"Atorvastatin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with mixed dyslipidemia\n* Subjects must agree to utilize adequate birth control methods and to adhere to the American Heart Association (AHA) diet\n\nExclusion Criteria:\n\n* Subjects with unstable medical conditions or medical conditions considered inappropriate in a clinical trial.\n* Patients who are taking certain medications or unstable dose of specific medications.\n* Women who are pregnant or plan on becoming pregnant, or women who are lactating.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percent Change in Triglycerides From Baseline to Final Visit","description":"\\[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.6","spread":"3.36"},{"groupId":"OG001","value":"-42.1","spread":"3.40"},{"groupId":"OG002","value":"-29.6","spread":"3.35"},{"groupId":"OG003","value":"-16.5","spread":"3.31"},{"groupId":"OG004","value":"-23.2","spread":"3.35"},{"groupId":"OG005","value":"-30.4","spread":"4.70"}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit","description":"\\[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"2.02"},{"groupId":"OG001","value":"12.6","spread":"2.08"},{"groupId":"OG002","value":"19.9","spread":"2.04"},{"groupId":"OG003","value":"6.3","spread":"1.96"},{"groupId":"OG004","value":"5.3","spread":"2.05"},{"groupId":"OG005","value":"6.2","spread":"2.75"}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit","description":"\\[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.7","spread":"1.91"},{"groupId":"OG001","value":"-35.4","spread":"1.93"},{"groupId":"OG002","value":"-3.4","spread":"1.90"},{"groupId":"OG003","value":"-37.1","spread":"1.85"},{"groupId":"OG004","value":"-39.7","spread":"1.92"},{"groupId":"OG005","value":"-46.0","spread":"2.61"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit","description":"\\[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.8","spread":"1.69"},{"groupId":"OG001","value":"-42.5","spread":"1.74"},{"groupId":"OG002","value":"-14.8","spread":"1.71"},{"groupId":"OG003","value":"-35.7","spread":"1.64"},{"groupId":"OG004","value":"-41.7","spread":"1.72"},{"groupId":"OG005","value":"-45.2","spread":"2.30"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit","description":"\\[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.3","spread":"3.72"},{"groupId":"OG001","value":"-53.5","spread":"3.74"},{"groupId":"OG002","value":"-36.5","spread":"3.66"},{"groupId":"OG003","value":"-26.2","spread":"3.63"},{"groupId":"OG004","value":"-35.6","spread":"3.66"},{"groupId":"OG005","value":"-38.9","spread":"5.13"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Total Cholesterol From Baseline to Final Visit","description":"\\[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.8","spread":"1.32"},{"groupId":"OG001","value":"-34.6","spread":"1.33"},{"groupId":"OG002","value":"-10.1","spread":"1.32"},{"groupId":"OG003","value":"-29.6","spread":"1.29"},{"groupId":"OG004","value":"-33.8","spread":"1.31"},{"groupId":"OG005","value":"-38.2","spread":"1.84"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit","description":"\\[(Week 12 Apo B minus baseline Apo B)/baseline Apo B\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.0","spread":"1.49"},{"groupId":"OG001","value":"-37.1","spread":"1.52"},{"groupId":"OG002","value":"-12.4","spread":"1.49"},{"groupId":"OG003","value":"-32.9","spread":"1.46"},{"groupId":"OG004","value":"-35.3","spread":"1.50"},{"groupId":"OG005","value":"-40.3","spread":"2.08"}]}]}]},{"type":"SECONDARY","title":"Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Final Visit","description":"\\[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP\\] x 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.2","spread":"24.76"},{"groupId":"OG001","value":"-42.9","spread":"25.11"},{"groupId":"OG002","value":"-12.4","spread":"24.65"},{"groupId":"OG003","value":"-29.6","spread":"24.18"},{"groupId":"OG004","value":"-30.3","spread":"25.08"},{"groupId":"OG005","value":"-31.9","spread":"34.50"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Headache","Diarrhea","Nausea","Myalgia","Upper respiratory tract infection"]}}}